Prenosis has secured a combined $40M in new capital—split evenly between a $20M Series A led by PACE Healthcare Capital and a $20M federal contract from BARDA. The funding supports the commercial rollout of Sepsis ImmunoScore® (the first FDA-authorized AI diagnostic for sepsis) and the development of a “comprehensive precision medicine platform” for conditions like pneumonia and ARDS. Prenosis already made history with the Sepsis ImmunoScore®, the first AI diagnostic tool for sepsis to receive FDA authorization. Building the Precision Medicine Clinical Trial NetworkPerhaps the most ambitious aspect of the announcement is the infrastructure play. This creates a “precision medicine clinical trial network” capable of rapidly identifying patients with specific biological traits.